



# Effective Health Care

## Treatments for Prostate Cancer Nomination Summary Document

### Results of Topic Selection Process & Next Steps

- Treatments for prostate cancer was found to be addressed by a 2008 AHRQ comparative effectiveness review titled *Comparative Effectiveness of Therapies for Clinically Localized Prostate Cancer*, which is in the process of being updated. The scope of this topic, including populations, interventions, comparators, and outcomes, will be further developed during the update process.
- When a draft of this update is completed, it will be posted on the AHRQ Web site and open for public comment. To sign up for notification when this and other EHC Program topics are posted for public comment, please go to <http://effectivehealthcare.ahrq.gov/getinvolved.cfm?involve=subscribe>.
- The original report may be accessed as follows:
  - Wilt TJ, Shamlivan T, Taylor B, MacDonald R, Tacklind J, Rutks I, Koeneman K, Cho C-S, Kane RL. Comparative Effectiveness of Therapies for Clinically Localized Prostate Cancer. Comparative Effectiveness Review No. 13. (Prepared by Minnesota Evidence-based Practice Center under Contract No. 290-02-0009.) Rockville, MD: Agency for Healthcare Research and Quality, February 2008. <http://effectivehealthcare.ahrq.gov/healthInfo.cfm?infotype=rr&ProcessID=9%20&DocID=79>

### Topic Description

**Nominator:** National non-governmental advisory group

**Nomination Summary:** The nominator questions the comparative effectiveness of treatments for prostate cancer including watchful waiting, surgery, proton beam radiation, and other radiation therapies.

**Key Questions from Nominator:** None

### Considerations

- The topic was found to be addressed by a 2008 AHRQ comparative effectiveness review titled *Comparative Effectiveness of Therapies for Clinically Localized Prostate Cancer*, which is in the process of being updated. Key questions from the 2008 report include:
  1. What are the comparative risks, benefits, short- and long-term outcomes of therapies for clinically localized prostate cancer?

2. How do specific patient characteristics, e.g., age, race/ethnicity, presence or absence of comorbid illness, preferences (e.g., tradeoff of treatment-related adverse effects vs. potential for disease progression), affect the outcomes of these therapies, overall and differentially?
3. How do provider/hospital characteristics affect outcomes overall and differentially (e.g., geographic region and volume)?
4. How do tumor characteristics, e.g., Gleason score, tumor volume, screen vs. clinically detected tumors, affect the outcomes of these therapies, overall and differentially?